

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD133/2 (293C3)-PE, human

RRID:AB_2661207

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-046, RRID:AB_2661207

Antibody Information

URL: http://antibodyregistry.org/AB_2661207

Proper Citation: Miltenyi Biotec Cat# 130-098-046, RRID:AB_2661207

Target Antigen: CD133/2 (293C3)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 4-2018; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-748. (RRID:AB_2726287).

Antibody Name: CD133/2 (293C3)-PE, human

Description: This monoclonal targets CD133/2 (293C3)

Target Organism: human

Clone ID: 293C3

Antibody ID: AB_2661207

Vendor: Miltenyi Biotec

Catalog Number: 130-098-046

Record Creation Time: 20250820T014031+0000

Record Last Update: 20250820T113344+0000

Ratings and Alerts

No rating or validation information has been found for CD133/2 (293C3)-PE, human.

Warning: Discontinued: 2021

Discontinued: 4-2018; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-748. (RRID:AB_2726287).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bellio C, et al. (2019) PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells. Molecular cancer research : MCR, 17(2), 431.

Bellio C, et al. (2019) The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells. Cancers, 11(11).